University of Utah Research Foundation

Mark Martin Jensen

Joseph Cappello

Glenn D Prestwich

Hamidreza Ghandehari

Wanjian Jia

Siam Oottamasathien

Azadeh Poursaid

Hamid Ghandehari

Described herein are in situ gelling compositions. The compositions include an anti-inflammatory polysaccharide and a gelling polymer, wherein the composition is a liquid prior to administration to a subject but converts to a gel upon administration to the subject. The compositions described herein have numerous applications with respect to the local treatment (reduction or prevention) of inflammation and/or tissue damage.

In situ gelling compositions for the treatment or prevention of inflammation and tissue damage

Described herein are chemoembolic compositions and agents. The compositions include one or more anti-cancer agents and a silk-elastinlike protein polymer, wherein the compositions are liquids prior to administration to a subject but convert to hydrogels upon administration to the subject. Administration of the chemoembolic compositions to tumor and/or tumor vasculature in a subject having cancer can result in reduced or inhibited blood flow to the tumor as well as localized, sustained release of the anti-cancer agent in the vicinity of the tumor. Reduction in blood flow, in turn, results in a reduction of tumor volume and/or inhibition of tumor growth, while localized release of the anti-cancer agent results in reduced systemic effects and lower overall toxicity of treatment with the compositions.

Methods for producing chemoembolic agents for the delivery of anti-cancer agents

Growing community of inventors

Salt Lake City, UT, United States of America

Mark Martin Jensen